

Amendments to the Specification:

Please replace the paragraph beginning at page 11, lines 9 through 14 with the following amended paragraph:

Figure 2A is a representation of a Western blot showing the quantitation of MDM2 protein in cells treated with an antisense oligonucleotide according to the present invention; ~~panel~~ Figure 2B is a representation of a Northern blot showing the quantitation of MDM2 mRNA in cells treated with an oligonucleotide according to the present invention; ~~panel~~ Figure 2C is a representation of a Western blot showing the quantitation of p21/WAF protein in cells treated with an oligonucleotide of the invention.

Please replace the paragraph beginning at page 12, lines 4 through 8 with the following amended paragraph:

Figures 7A and B are graphical representations showing the relative luciferase activity in JAR cells transfected with *BP100-luc* that had been treated with camptothecin (CPT) and oligonucleotide AS5. Figure 7C ~~7B~~ is a graphical representation showing the relative luciferase activity in MCF-7 cells incubated CPT, BP100-luc and CMV-lacZ reporter plasmids, and oligonucleotides in the presence of cationic lipids.